TY - JOUR
T1 - Chronic fatigue syndrome
T2 - Inflammation, immune function, and neuroendocrine interactions
AU - Klimas, Nancy G.
AU - Koneru, Anne O.Brien
PY - 2007/12
Y1 - 2007/12
N2 - Investigations into the underlying cause of chronic fatigue syndrome have advanced the field considerably in the past year. Gene microarray data have led to a better understanding of pathogenesis. Recent research has evaluated genetic signatures, described biologic subgroups, and suggested potential targeted treatments. Acute viral infection studies found that initial infection severity was the single best predictor of persistent fatigue. Genomic studies showed that persistent cases express Epstein Barr virus-specific genes and demonstrate abnormalities of mitochondrial function. Studies of immune dysfunction extended observations of natural killer cytotoxic cell dysfunction of the cytotoxic T cell through quantitative evaluation of intracellular perforins and granzymes. Other research has focused on a subgroup of patients with reactivated viral infection. These advances should result in targeted therapies that impact immune function, hypothalamic-pituitary-adrenal axis regulation, and persistent viral reactivation.
AB - Investigations into the underlying cause of chronic fatigue syndrome have advanced the field considerably in the past year. Gene microarray data have led to a better understanding of pathogenesis. Recent research has evaluated genetic signatures, described biologic subgroups, and suggested potential targeted treatments. Acute viral infection studies found that initial infection severity was the single best predictor of persistent fatigue. Genomic studies showed that persistent cases express Epstein Barr virus-specific genes and demonstrate abnormalities of mitochondrial function. Studies of immune dysfunction extended observations of natural killer cytotoxic cell dysfunction of the cytotoxic T cell through quantitative evaluation of intracellular perforins and granzymes. Other research has focused on a subgroup of patients with reactivated viral infection. These advances should result in targeted therapies that impact immune function, hypothalamic-pituitary-adrenal axis regulation, and persistent viral reactivation.
UR - https://www.scopus.com/pages/publications/37349018273
UR - https://www.scopus.com/pages/publications/37349018273#tab=citedBy
U2 - 10.1007/s11926-007-0078-y
DO - 10.1007/s11926-007-0078-y
M3 - Review article
C2 - 18177602
AN - SCOPUS:37349018273
SN - 1523-3774
VL - 9
SP - 482
EP - 487
JO - Current Rheumatology Reports
JF - Current Rheumatology Reports
IS - 6
ER -